Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development
Biologically-based therapies increasingly rely on the endocytic cycle of internalization and exocytosis of target receptors for cancer therapies. However, receptor trafficking pathways (endosomal sorting (recycling, lysosome localization) and lateral membrane movement) are often dysfunctional in can...
Saved in:
Main Authors: | Manar Hammood (Author), Andrew W. Craig (Author), Jeffrey V. Leyton (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development
by: Kira-Lee Koster, et al.
Published: (2022) -
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
by: Yan Liang, et al.
Published: (2024) -
Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
by: Xiaolan Xu, et al.
Published: (2024) -
The Chemistry Behind ADCs
by: Vesela Kostova, et al.
Published: (2021) -
Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)
by: Peng-Hui Wang, et al.
Published: (2024)